Wirkung von Pamidronat auf Beschwerdebild und Knochenstoffwechsel bei fibröser Dysplasie und McCune-Albright-Syndrom
- 1 June 1998
- journal article
- other
- Published by Springer Nature in Medizinische Klinik
- Vol. 93 (6) , 352-359
- https://doi.org/10.1007/bf03044679
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Long-Term Effects of Intravenous Pamidronate in Fibrous Dysplasia of BoneJournal of Bone and Mineral Research, 1997
- Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome.Journal of Clinical Investigation, 1996
- Pamidronate treatment in children with fibrous dysplasia and osteogenesis imperfectaBone, 1995
- Long-term effects of intravenous pamidronate in fibrous dysplasia of boneThe Lancet, 1994
- Activating Mutations of the Stimulatory G Protein in the McCune–Albright SyndromeNew England Journal of Medicine, 1991
- PamidronateDrugs, 1991
- Estrogen Receptors in Bone in a Patient with Polyostotic Fibrous Dysplasia (McCune-Albright Syndrome)New England Journal of Medicine, 1988
- Panostotic fibrous dysplasia: A congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphatasemia, and hypophosphatemiaAmerican Journal of Medical Genetics, 1983
- A Case of Albright's Syndrome Treated with CalcitoninActa Orthopaedica, 1979
- Syndrome Characterized by Osteitis Fibrosa Disseminata, Areas of Pigmentation and Endocrine Dysfunction, with Precocious Puberty in FemalesNew England Journal of Medicine, 1937